Diamond jewelry isn’t exactly an impulse buy, so it’s important to weigh your options carefully. As a fashion writer and regular contributor to Forbes Vetted’s jewelry stories, I researched popular ...

Logitech's G923 has made the brand synonymous with beginner’s racing wheels, but it’s now shooting for the fences of pro simulation racing with the Logitech G Pro Racing Wheel. The G Pro lives up to ...

It’s no longer possible to buy a new car with a starting price of under $20,000, but a variety of models still deserve consideration just beyond that. We’ve ordered the list by base price with an ...

Buy now, pay later (BNPL) loans, also known as point-of-sale loans, allow consumers to pay for purchases in small installments, usually over several weeks. Unlike credit cards, this short-term ...

The best triathlon wheels have highly developed aerodynamics to give you the edge when every second counts. They're optimised for the high speeds that competitors in triathlons maintain and for ...

With a starting price of $28,995 (including destination), the Chevrolet Bolt has returned and taken the crown from the Nissan Leaf as the cheapest new electric vehicle you can buy. SUVs and crossovers ...

ETFs offer diversified exposure to various sectors, reducing the risk of single-stock investments. Low expense ratios in ETFs like the Vanguard S&P 500 (0.03%) enhance investor returns. ETFs allow ...

Farran Powell is the managing editor of investing at Forbes Advisor. She was previously the assistant managing editor of investing at U.S. News & World Report. Her work has appeared in numerous ...

These are tested and vetted markdowns you won’t want to miss Written By Written by Editorial, Buy Side Shopping and money advice you can trust. Separate from The Wall Street Journal newsroom — they ...

Stocks priced under $10 may seem appealing to bargain hunting investors, but a low stock price is often a sign of poor business fundamentals or a broken operating model. Finding high-quality ...

Investing in biotechnology stocks has always required a high risk tolerance and the patience to wait years, even decades, for results. These companies drive medical innovation, developing therapies ...

Growth stocks outperformed their value counterparts for much of 2025, but that trend started to shift toward the end of the year. Value stocks have seen more consistent returns heading into 2026. They ...